Andreas Gomoll
Orthopaedic Surgery · New York, NYNPI 1649259946
Payments from drug & device makers
What this record shows
This record is dominated by other: $282,051 of the $413,210 with a category attached, or 68.3%. Smith+Nephew accounts for 78.4% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2022 at $259,727 and has fallen 86.8% since, to $34,265 in 2025. Among orthopaedic surgery clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 136 payments — averaging $3038.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$324K
- Organogenesis Inc.$28K
- Vericel Corporation$25K
- Joint Restoration Foundation, Inc.$13K
- Bioventus LLC$10K
- Moximed, Inc$8K
- plus $7K from 10 others
Across 48 payments — averaging $4584.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Smith+Nephew$189K
- Moximed, Inc$13K
- Vericel Corporation$7K
- Cartiheal (2009) LTD.$7K
- Bioventus LLC$3K
- Aesculap Biologics, LLC$1K
- plus $934 from 1 others
What the payments were for
- Royalty or licence$26,8516%
- Consulting fees$63,85215%
- Speaking & faculty fees$33,5018%
- Travel & lodging$2,4011%
- Food & beverage$4,4391%
- Gifts$1140%
- Other$282,05168%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 50 | $323,874 |
| Organogenesis Inc. | 15 | $27,551 |
| Vericel Corporation | 21 | $25,010 |
| Joint Restoration Foundation, Inc. | 9 | $12,521 |
| Bioventus LLC | 14 | $9,564 |
| Moximed, Inc | 7 | $7,698 |
| Fidia Pharma USA Inc. | 3 | $2,542 |
| Linvatec Corporation | 3 | $2,141 |
| Pacira Therapeutics, Inc. | 4 | $774 |
| Pacira Pharmaceuticals Incorporated | 1 | $623 |
| Miach Orthopaedics, Inc. | 3 | $581 |
| Engage Uni, LLC | 1 | $114 |
| Johnson & Johnson | 2 | $68 |
| Cartiheal (2009) LTD. | 1 | $64 |
| Aesculap Biologics, LLC | 1 | $52 |
| DJO, LLC | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Engage Partial Knee System$282,165
- ReNu$26,851
- MACI$16,400
- MISHA KNEE SYSTEM, SMALL, LEFT$7,549
- Hymovis$2,500
- LINVATEC KNEE PRESERVATION SYSTEM$2,000
- Zilretta$700
- EXPAREL$623
- Apligraf$557
- NexoBrid$150
- PuraPly$143
- Bone Anchors with Arthroscopic Delivery System$141
- FAST-FIX$113
- Video Accessories$110
- BioBrace 23mm$105
How this compares
$413,210 in reported general payments places this provider in the 95th percentile of 1,079 orthopaedic surgery providers in New York.
Other orthopaedic surgery in New York
- Anthony RomeoNew York$26.8M
- Lawrence LenkeNew York$26.8M
- Edwin SuNew York$13.2M
- William RicciNew York$11.6M
- Steven HaasNew York$11.3M
- Giles ScuderiNew York$10.7M
- Joseph ZuckermanNew York$9.9M
- Evan FlatowNew York$9.6M
- Bradford ParsonsNew York$9.4M
- Geoffrey WestrichNew York$7.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.